By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompanied by periodic exacerbations. Drug therapy is an important component in the overall treatment of prostate disease. In addition, treatment often ends in defeat due to improper therapy, missed medications, and, when the condition subsides, ignoring the disease.
Thus, 20-30% of patients are not satisfied with the treatment, do not feel a reduction in the symptoms of urination disorders and an improvement in quality of life. This is most likely due to an incorrect assessment of the function of the lower urinary tract in men with BPH and, consequently, the choice of inadequate treatment.
As you know, prostatitis is acute and chronic (CP), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80–90%, including prostatodynia - 20–30%.
The most common is chronic abacterial prostatitis, which must be controlled and timely worsened with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5α-reductase inhibitors (finasteride, dutasteride);
- α-blockers (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (insect-derived products).
At the same time, in 13-30% of the effect of the use of α-blockers does not occur within 3 months of treatment - further therapy with drugs of this group is not desirable.
When prescribing finasteride, the doctor must be prepared for the fact that the most significant side effects of the drug: impotence, decreased libido, decreased ejaculate volume can lead to withdrawal of the drug by the patient.
Treatment of BPH and prostatitis is an important, not completely resolved urological problem.
Frequent exacerbations of CP in the absence of indications for prostate surgery force the doctor to use additional methods in drug treatment. Often, the presence of concomitant CP worsens the course of BPH, in 80% of cases in the prostate with benign hyperplasia.
Modern medicine provides us with new possibilities for the treatment of CP and BPH and the prevention of worsening.